Eosinophil and Cationic Protein Levels in Patients Treated With Dupilumab: A Real-Life Study.
作者信息
Castillo María Alejandra, Correa-Borit Jorge, Laorden Daniel, Adrianzen Fiorella, Villamañán Elena, Romero David, Quirce Santiago, Domínguez-Ortega Javier
机构信息
Department of Pneumology, La Paz University Hospital, Madrid, Spain.
Department of Allergy, La Paz University Hospital, Madrid, Spain.
出版信息
Open Respir Arch. 2025 May 17;7(3):100444. doi: 10.1016/j.opresp.2025.100444. eCollection 2025 Jul-Sep.
Abstract
摘要
相似文献
1
Eosinophil and Cationic Protein Levels in Patients Treated With Dupilumab: A Real-Life Study.使用度普利尤单抗治疗患者的嗜酸性粒细胞和阳离子蛋白水平：一项真实世界研究
Open Respir Arch. 2025 May 17;7(3):100444. doi: 10.1016/j.opresp.2025.100444. eCollection 2025 Jul-Sep.
2
Real-world Effectiveness of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-analysis.度普利尤单抗治疗嗜酸性食管炎的真实世界疗效：一项系统评价和Meta分析
J Clin Gastroenterol. 2025 Jul 1;59(6):483-490. doi: 10.1097/MCG.0000000000002146.
3
Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab.使用度普利尤单抗治疗的特应性皮炎患者的银屑病风险
JAMA Dermatol. 2025 Jun 18. doi: 10.1001/jamadermatol.2025.1578.
4
Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Dupilumab on Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV) in Uncontrolled Moderate-To-Severe Asthma.度普利尤单抗对未控制的中度至重度哮喘患者支气管扩张剂使用前1秒用力呼气容积（FEV）的半机制群体药代动力学/药效学（PK/PD）建模
CPT Pharmacometrics Syst Pharmacol. 2025 Aug;14(8):1370-1380. doi: 10.1002/psp4.70057. Epub 2025 Jun 19.
5
Leukocytoclastic Vasculitis With Eosinophilia in a Patient Receiving Dupilumab Therapy.接受度普利尤单抗治疗的患者出现伴有嗜酸性粒细胞增多的白细胞破碎性血管炎。
Cureus. 2025 May 16;17(5):e84252. doi: 10.7759/cureus.84252. eCollection 2025 May.
6
Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study.度普利尤单抗与哮喘患者的淋巴瘤风险：一项基于人群的队列研究。
Eur Respir J. 2025 Jun 19. doi: 10.1183/13993003.00139-2025.
7
Dupilumab Efficacy in Children With Eosinophilic Esophagitis With Prior Swallowed Topical Corticosteroid Use: A Subgroup Analysis.度普利尤单抗在既往使用过吞咽型局部皮质类固醇的嗜酸性食管炎儿童中的疗效：一项亚组分析。
Am J Gastroenterol. 2025 Jun 18. doi: 10.14309/ajg.0000000000003599.
8
Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab.使用度普利尤单抗治疗的哮喘和慢性鼻-鼻窦炎伴鼻息肉患者的嗜酸性粒细胞阳离子蛋白变化
Life (Basel). 2023 Sep 8;13(9):1884. doi: 10.3390/life13091884.
9
Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series.曲罗芦单抗作为特应性皮炎中与度普利尤单抗相关的关节痛的治疗替代方案：一项多中心病例系列研究
J Clin Aesthet Dermatol. 2025 May 1;18(5):16-19.
10
Neonatal necrotizing enterocolitis attenuates adult asthma via eosinophil ferroptosis.新生儿坏死性小肠结肠炎通过嗜酸性粒细胞铁死亡减轻成人哮喘。
Cell Signal. 2025 Sep;133:111878. doi: 10.1016/j.cellsig.2025.111878. Epub 2025 May 16.
本文引用的文献
1
The value of biomarkers in the therapy of CRSwNP with biologicals-a long-term follow-up of dupilumab therapy.生物标志物在生物制剂治疗 CRSwNP 中的价值 - 度普利尤单抗治疗的长期随访。
Eur Arch Otorhinolaryngol. 2024 Sep;281(9):4789-4805. doi: 10.1007/s00405-024-08574-4. Epub 2024 May 6.
2
Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective.度普利尤单抗对不同疾病表型和严重程度的哮喘功能、炎症及患者报告结局的疗效：一项真实世界研究视角
Biomedicines. 2024 Feb 8;12(2):390. doi: 10.3390/biomedicines12020390.
3
Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab.使用度普利尤单抗治疗的哮喘和慢性鼻-鼻窦炎伴鼻息肉患者的嗜酸性粒细胞阳离子蛋白变化
Life (Basel). 2023 Sep 8;13(9):1884. doi: 10.3390/life13091884.
4
[Consensus document for severe asthma in adults. 2022 update].[成人重度哮喘共识文件。2022年更新]
Open Respir Arch. 2022 Jul 2;4(3):100192. doi: 10.1016/j.opresp.2022.100192. eCollection 2022 Jul-Sep.
5
Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL).度普利尤单抗治疗伴有鼻息肉的重度难治性慢性鼻-鼻窦炎（CRSwNP）：一项多中心观察性 IV 期真实世界研究（DUPIREAL）。
Allergy. 2023 Oct;78(10):2669-2683. doi: 10.1111/all.15772. Epub 2023 May 26.
6
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.根据特应性特征和是否存在伴有鼻息肉的慢性鼻-鼻窦炎，评估度普利尤单抗治疗重度 2 型哮喘患者的真实世界疗效。
Front Immunol. 2023 Mar 30;14:1121237. doi: 10.3389/fimmu.2023.1121237. eCollection 2023.
7
Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma.嗜酸性阳离子蛋白作为重度哮喘患者抗体治疗反应的标志物
ERJ Open Res. 2022 Sep 26;8(3). doi: 10.1183/23120541.00138-2022. eCollection 2022 Jul.
8
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management.度匹鲁单抗引起的嗜酸性粒细胞增多症：文献复习及临床管理算法建议。
Expert Rev Respir Med. 2022 Jul;16(7):713-721. doi: 10.1080/17476348.2022.2090342. Epub 2022 Jun 23.
9
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.度普利尤单抗治疗中重度哮喘患者的长期安全性和有效性（TRAVERSE）：一项开放标签扩展研究。
Lancet Respir Med. 2022 Jan;10(1):11-25. doi: 10.1016/S2213-2600(21)00322-2. Epub 2021 Sep 28.
10
Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab.伴有鼻息肉的慢性鼻-鼻窦炎：通过靶向抑制 IL-4Rα阻断 IL-4 和 IL-13 治疗的机制见解。
Expert Rev Clin Immunol. 2020 Dec;16(12):1115-1125. doi: 10.1080/1744666X.2021.1847083. Epub 2020 Nov 15.
Zotero 插件